AbbVie (ABBV) share buybacks: $980M
AbbVie spent $980M buying back its own shares in the year ended Dec 31, 2025, down 42.6% from $1.7B a year earlier.
From AbbVie's filings with the SEC · Read the filing · ABBV stock page
AbbVie share buybacks by year
#210 of 1,890 US companies by share buybacks · See the full ranking
| Year ended | Share buybacks | Change |
|---|---|---|
| Dec 31, 2025 | $980M | -43% |
| Dec 31, 2024 | $1.7B | -13% |
| Dec 31, 2023 | $2B | +33% |
| Dec 31, 2022 | $1.5B | +59% |
| Dec 31, 2021 | $934M | – |
Share buybacks of similar companies
Companies in the same industry as AbbVie, by SEC industry code, with the closest share buybacks. Each name opens the same page for that company.
| Company | Share buybacks, latest year | Year ended |
|---|---|---|
| Zoetis | $3.2B | Dec 31, 2025 |
| Vertex Pharmaceuticals Inc / Ma | $2B | Dec 31, 2025 |
| Royalty Pharma | $1.2B | Dec 31, 2025 |
| United Therapeutics | $1B | Dec 31, 2025 |
| AbbVie | $980M | Dec 31, 2025 |
| Abbott Laboratories | $893M | Dec 31, 2025 |
| Viatris | $500M | Dec 31, 2025 |
Questions and answers
What is AbbVie's share buybacks?
AbbVie spent $980M buying back its own shares in the year ended Dec 31, 2025, down 42.6% from $1.7B a year earlier.
Numbers as reported in AbbVie's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology